AKAP12 and gastric adenocarcinoma: AKAP12, a widely studied tumor suppressor in various cancers, has been demonstrated to be an independent prognostic factor with excellent predictive performance for the prognosis of STAD patients, and its expression is significantly associated with immune cell infiltration, immune pathways, and immunomodulators (82).